Dyne Therapeutics, Inc.
19.19USD
-1.1200 (-5.51%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | — | — | — | 0.0 | 52.8M |
| Q1 | — | — | — | — | — | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | 0.0 | — |
| Q4 | — | — | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.23 | -3.95 | -3.37 | -3.47 | -3.55 | -3.36 |
| Q1 | -.690 | -.780 | -.810 | -1.05 | -.730 | — |
| Q2 | -1.01 | -1.08 | -.700 | -.970 | -1.08 | — |
| Q3 | -.800 | -.990 | -.960 | -.760 | -.889 | — |
| Q4 | -.730* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -1.09* |
| -.880* |
| -.730* |
| -.892 |
| — |